Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeeing Machines Regulatory News (SEE)

Share Price Information for Seeing Machines (SEE)

Share Price is delayed by 15 minutes
Get Live Data
4.60    -0.05 (-1.08%)
Bid:
4.55
Ask:
4.615
Spread: 0.065 (1.429%)
Market Cap: £220.78m
SEE Live PriceLast checked at - London Stock Exchange

Intraday Seeing Machines Share Chart

Fundraising

24 Sep 2007 13:00

Seeing Machines Limited24 September 2007 24 September 2007 Seeing Machines Limited ("Seeing Machines" or the "Company") Fund raising, issue of shares, general meeting, and change in shareholding Seeing Machines (AIM: SEE), a leading developer of advanced computer basedimaging software systems, is pleased to announce that it has raised up toΒ£1,287,130 million before expenses via the issue of 51,485,206 new ordinaryshares at 2.5p per share through a placing (the "Placing"). The Placing is to beconducted in two tranches as follows: β€’ tranche 1 of 8,348,000 Ordinary Shares β€’ tranche 2 of 43,137,206 Ordinary Shares conditional on shareholder approval Tranche 1 has been concluded today providing additional working capital to theCompany of A$500,000 (Β£208,700). 8,348,000 new Ordinary Shares were issued andallotted on 24 September 2007. Application has been made for these 8,348,000 newOrdinary Shares to be admitted to trading on AIM and dealings are expected tocommence on 27 September 2007. Following the issue of these 8,348,000 newOrdinary Shares the issued share capital of the Company is 264,512,929 OrdinaryShares. A group of investors has agreed to subscribe for Tranche 2 of 43,137,206Ordinary Shares, conditional on shareholder approval which will be sought at aGeneral Meeting of the Company in Acton, ACT, Australia on 26 October 2007. A further tranche of up to 4,514,794 Ordinary Shares, is expected to concludeshortly and a separate announcement will be made when the details are available.If all three tranches are successfully completed, the final outcome will resultin a total raising of up to Β£1.4 million before expenses, via the issue of up to56,000,000 new ordinary shares at the 2.5p per share placing price. A circular containing a Notice of Meeting convening a General Meeting of theCompany for the purpose of seeking the required shareholder approval has beenposted to shareholders and will be available from the Company's web site todaywww.seeingmachines.com. The proceeds of the placing will be used to commercialise the Company'sproducts, including: the TrueField Analyzer ("TFA"), a medical device that helpsclinicians diagnose glaucoma and other eye diseases, and has recently receivedFDA approval; the Driver State Sensor ("DSS") system, which monitors driverfatigue and distraction; and the faceTRACKING API ("API"), a software libraryoffering the Company's core technology to third party system developers on alicensing model. A presentation by the Company provided to potential investors in the Placing isavailable from the Company's website at www.seeingmachines.com. The Tranche 1 shares were issued to the Australian National University.Following the issue of these 8,348,000 new ordinary shares, the Company is awareof the following relevant changes in substantial/significant shareholdings asdefined in the AIM Rules for Companies: +--------------+-----------------------------+-----------------------------+| | To 23 September 2007 | 24 September 2007 |+--------------+--------------+--------------+--------------+--------------+|Shareholder | No. of shares|% shareholding| No. of shares|% shareholding|| | held| | held| |+--------------+--------------+--------------+--------------+--------------+|JATS | 85,594,176| 33.41| 85,594,176| 32.36||Technology Pty| | | | ||Limited | | | | |+--------------+--------------+--------------+--------------+--------------+|Australian | 28,114,687| 10.98| 36,462,687| 13.78||National | | | | ||University | | | | |+--------------+--------------+--------------+--------------+--------------+|Volvo | 23,226,073| 9.07| 23,226,073| 8.78||Technological | | | | ||Development | | | | |+--------------+--------------+--------------+--------------+--------------+ --- ENDS --- Enquiries: Seeing Machines Limited Insinger de Beaufort Parkgreen Communications Nick Cerneaz, CEO Peter Ward Ben Knowles Erica Nelson +61 (0) 2 6125 6501 +44 (0) 20 7190 7015 +44 (0) 20 7851 7480 www.seeingmachines.com Notes to editors: About Seeing Machines Seeing Machines is an award winning Technology Company which focuses on visionbased human machine interfaces. Formed in 2000 in Canberra, Australia, SeeingMachines' purpose is to commercialise its computer-vision across a range ofindustries and applications. Seeing Machines deliver advanced computer vision solutions for researches anddevelopers in human factors, transportation safety, computer human interaction,robotics, medical research and psychology. The flagship product faceLAB(R)provides an automated and contact-free gaze and head tracking technology, itsolves the problem of observing human behaviour naturally, non-intrusively andwith a high degree of accuracy and usability. Building on these unique facetracking and pupil measurement and monitoring capabilities, the TrueFieldAnalyzer(R) is new medical device to assist clinicians detect and manage eyediseases such as glaucoma. The TrueField Analyzer(R) offers a new objective method to help doctors diagnoseand manage a range of eye diseases including glaucoma, age related maculardegeneration and diabetic retinopathy. Glaucoma affects about 2-3% of thepopulation over 40 years of age and is a leading source of blindness. Unlikemost other devices available to the clinician the TrueField Analyzer is acompletely objective test and it is quick and easy for patients and techniciansalike. The device measures both eyes concurrently and due to the reliabilitythat arises from the objective nature of the test, it has the potential tobecome a new standard in the measurement of visual field defects and thus in thediagnosis and management of disease such as glaucoma. More generally Seeing Machines' computer vision systems are able to measure theorientation and position of a human head, estimate eye-gaze direction, detecteye blinks and track other facial features. This functionality is achievedentirely though visual means, using video cameras connected to advanced imageprocessing software, with no attachments required on the subject. Products suchas faceLAB(R) are designed to allow human factors researchers and designers toassess the interaction of an operator in an environment and this findsapplication in designing operator environments, such as cockpits for cars,trucks, trains, and aeroplanes for instance, and other industrial designapplications, as well as medical and psychological research situations. Thetechnology has been developed into the Driver State Sensor (DSS2) product forapplication in monitoring vehicle drivers and if it detects drowsiness (fatigue)or that the driver is distracted and their attention has been diverted from theroad, alarms are raised to alert the driver to these events. In largerdeployments, such as in fleet and mining equipment operations, the data isavailable in both real-time and off-line modes for fleet management, drivertraining and awareness programs The systems work in real-time, enabling the behaviour of subjects to be trackedin real-time. This technology is paving the way in promoting safer drivingconditions and works to enhance the driving experience and to eliminateaccidents caused through driver drowsiness or distraction. There are many different sectors that can benefit from this revolutionarysoftware, for which it has been developed, including: automotive; academicresearch; medicine/healthcare; defence; autostereoscopy (next generationdisplays); sport; and games. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
12th May 20267:00 amRNSUS$3.8m Order for Guardian BdMS
6th May 20267:00 amRNSQ3 FY2026 Quarterly KPIs
20th Apr 202612:30 pmRNSHolding(s) in Company
10th Apr 20268:53 amRNSStatement re alleged cyber threat
27th Mar 20267:00 amRNSHalf-year Financial Report
24th Feb 20267:00 amRNS-RPublication of Investor Presentation
18th Feb 20267:00 amRNSTrading Update - H1 FY2026
13th Feb 20267:30 amRNSAppointment of Joint Broker
11th Feb 20267:00 amRNSQ2 FY2026 Quarterly KPIs
13th Jan 202612:00 pmRNS-R3D Cabin Perception Mapping breaks new ground
6th Jan 20267:00 amRNSAgreement
5th Jan 20267:00 amRNSHolding(s) in Company
5th Jan 20267:00 amRNS-R3D Cabin Perception Mapping to be unveiled at CES
2nd Jan 20267:00 amRNS-RSeeing Machines Announces Future Mobility Group
2nd Jan 20267:00 amRNS-RSeeing Machines Announces Future Mobility Group
17th Dec 20257:00 amRNS-RTechnical Paper Series - Intoxication launched
4th Dec 20257:00 amRNS-RSeeing Machines 2025 Guardian Insights Report
27th Nov 20257:00 amRNSResults of AGM
26th Nov 20257:30 amRNSJapanese Auto Award and Extended European Program
12th Nov 20257:05 amRNSQ1 FY2026 Quarterly KPIs
12th Nov 20257:00 amRNSGuardian order from US-based multinational company
6th Nov 20257:05 amRNS-RCollaboration with Magna milestone in China
3rd Nov 20257:00 amRNSBoard Changes
3rd Nov 20257:00 amRNSNotice of Annual General Meeting
30th Oct 20257:00 amRNSLATAM Distributor Orders 1,300 Guardian Units
29th Oct 20257:00 amRNSAdvanced Development Project with Japanese OEM
8th Oct 20257:00 amRNSUS$1.8m expansion order for Guardian BdMS
26th Sep 20257:00 amRNSExpanding Guardian prospects across Europe
25th Sep 20257:00 amRNSFY2025 Results and Annual Financial Report
24th Sep 20257:20 amRNSFirst Guardian contract through Mitsubishi
10th Sep 20257:05 amRNS-RSeeing Machines Launches Impairment Capability
10th Sep 20257:00 amRNSNotice of Results and Presentation
29th Aug 202510:10 amRNSDirector Dealing
21st Aug 20257:00 amRNSFY2025 Trading Update
5th Aug 20257:00 amRNSQ4 FY2025 Quarterly KPIs
30th Jun 20257:00 amRNSMitsubishi Electric Europe Guardian collaboration
27th Jun 20257:00 amRNSUS Guardian Gen 3 trial with Mitsubishi Electric
16th Jun 20258:59 amRNS$1.2 Million Agreement with Global Auto Leader
9th May 20252:31 pmRNSDirector dealing
1st May 20257:00 amRNSQ3 FY2025 Quarterly KPIs
29th Apr 20259:58 amRNSNotification of Major Holdings
8th Apr 20258:53 amRNSHoldings in Company
8th Apr 20257:00 amRNSDirector/PDMR Shareholding
4th Apr 20257:00 amRNSDirector dealing
2nd Apr 202511:00 amRNSLondon presentation for investors and analysts
2nd Apr 20257:00 amRNSDirector dealing
2nd Apr 20257:00 amRNSDirector dealing
1st Apr 202512:00 pmRNS-RSeeing Machines Announces 3D Camera Technology
31st Mar 20257:00 amRNSDirector/PDMR Shareholding
28th Mar 20257:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.